Formulation and Evaluation of Ophthalmic Emulgel Using Tobramycin and Dexamethasone

Abstract

In this study, a combination of medications will be chosen to create emulgel that can be administered via the ocular route. Patient compliance, treatment adherence, and resident time in ocular tissues may all be enhanced by the new combination's simultaneous administration and prolonged release of the two medications. Gel and emulsion will be combined to create Emulgel. After being produced independently, the gel and emulsion are combined. The aqueous phase and oil phase are separated and combined to create the emulsion. We have chosen tobramycin and dexamethasone as the APIs for this emulgel. They are used in conjunction with corticosteroids and antibiotics. It is used to the eye to stop long-term harm that could result from specific eye issues. The produced formulation is assessed using physical examination, pH measurement, rheological analysis, drug content determination, spreadability, diffusion analysis, in-vitro drug release kinetic analysis, and antibacterial activity. Optimized emulgel formulation may enable simultaneous and prolonged release of the two medications. Patient compliance and, consequently, therapy adherence may be enhanced by the ability to administer hydrophilic and hydrophobic drugs using the same formulation without the need for two drops.